cureVision rethinks wound healing and scales up with strategic partners
Pioneer has successfully completed its financing round.
Potsdam, 7 October 2025 – The medical technology company cureVision, a pioneer in the field of AI-supported medical imaging, has successfully completed its financing round. The company offers a novel solution for fully-automated 3D wound measurement, including bacterial scanning. The investments were provided by the Companisto Business Angel Network, Brandenburg Kapital, BioLab Holdings, Inc., and other co-investors. cureVision will use the capital to further develop its AI technology, scale its sales structure, and advance preparations for its US market entry in 2026.
cureVision: multiple award winner for innovative wound analysis
“cureVision's mission is to make next-generation medical imaging available worldwide. With the support of Brandenburg Kapital, Companisto, and BioLab Holdings, we are ideally positioned to scale internationally and push for FDA approval,” says Richard Fobo, CEO of cureVision.
Strategic partners promote international growth ambitions
Brandenburg Kapital, a subsidiary of ILB, has many years of experience in financing and supporting innovative companies at the interface of artificial intelligence and healthcare. “We see great potential in cureVision's technology and are looking forward to accompanying the company through its next phase of growth – especially as the company will be scaling its sales structure from Brandenburg,” says Thomas Krause, Managing Director of Brandenburg Kapital.
Companisto, Europe's leading network for business angel syndication, has been supporting cureVision in CapTable since 2022. Andreas Fakler, Investment Director, says: “The startup and its founding team impressed not only our investment team, but also our affiliated angel investors.”
The round was strengthened by the participation of BioLab Holdings from the USA: “We are delighted to support cureVision. We see a high demand for the cureVision solution in the US and will work together to prepare for market entry,” said Jaime Leija, CEO of the Arizona-based company.
About cureVision
cureVision is a young company specializing in improving the diagnosis of chronic wounds through the use of artificial intelligence (AI) and advanced medical imaging. cureVision has received numerous awards, including the Health-i Award, Novartis' digital health prize, the Eugen Münch Prize from the Röhn Foundation, the Bavarian Innovation Prize, and the German Health Award.
About BioLab Holdings Inc.
BioLab Holdings, Inc. is a Phoenix, Arizona-based manufacturer of medical products with a focus on wound healing. BioLab contributes to wound healing with innovative products, creating a continuum of care for providers and patients.
About Companisto
With over 4,000 business angels, Companisto is the largest business angel network in the DACH region and has already invested more than 300 million euros in startups through 175,000 investors. This has made Companisto one of the most active venture capitalists in the German-speaking world for over ten years. Startups benefit from a digital investment process, direct access to capital, and a strong network of experienced angels. Companisto supports companies from the early stages through to international follow-up financing.
About Brandenburg Kapital/ ILB
Brandenburg Kapital GmbH is a subsidiary of the Investment Bank of the State of Brandenburg (ILB). Since 1993, it has been supporting Brandenburg-based companies as the venture capital arm of ILB by acquiring equity interests and making equity-like investments. As a public venture capital company, experienced lead investor, and active partner, Brandenburg Kapital ensures a strong equity base for start-ups and small and medium-sized enterprises in the state of Brandenburg on the basis of a stable corporate environment. The equity fund currently has around 100 million euros available for this purpose. The funds for the Brandenburg Kapital fund, which was established on behalf of the Brandenburg Ministry of Economic Affairs, are currently provided from the European Regional Development Fund and ILB's own resources.
With a total of eleven funds, financed by funds from the state, the EU, KfW, and ILB's own resources amounting to about 338 million euros, around 300 Brandenburg companies have been supported with venture capital and/or mezzanine financing over the last 32 years. Further information is available at: www.brandenburg-kapital.de